PTGS2-899G > C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

A. Murad; S. J. Lewis; G. Davey Smith; S. M. Collin; L. Chen; F. C. Hamdy; D. E. Neal; J. Donovan; R. M. Martin

doi:10.1038/pcan.2009.18

PTGS2-899G > C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

A. Murad, S. J. Lewis, G. Davey Smith, S. M. Collin, L. Chen, F. C. Hamdy, D. E. Neal, J. Donovan, R. M. Martin

Research output: Contribution to journal › Review article › peer-review

18 Scopus citations

Abstract

Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G > C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (n_cases = 1608, n_controls = 3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (OR_{CC & GC v GG} = 1.05, 95% confidence interval (CI) = 0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled OR_{CC & GC v GG} = 1.04, 95% CI = 0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.

Original language	English
Pages (from-to)	296-300
Number of pages	5
Journal	Prostate Cancer and Prostatic Diseases
Volume	12
Issue number	3
DOIs	https://doi.org/10.1038/pcan.2009.18
State	Published - 2009
Externally published	Yes

Access to Document

10.1038/pcan.2009.18

Cite this

@article{b50f48b6ac8e430aa355d8b72d9ee1d2,

title = "PTGS2-899G > C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis",

abstract = "Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G > C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (ncases = 1608, ncontrols = 3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (ORCC & GC v GG = 1.05, 95% confidence interval (CI) = 0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled ORCC & GC v GG = 1.04, 95% CI = 0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.",

author = "A. Murad and Lewis, {S. J.} and Smith, {G. Davey} and Collin, {S. M.} and L. Chen and Hamdy, {F. C.} and Neal, {D. E.} and J. Donovan and Martin, {R. M.}",

year = "2009",

doi = "10.1038/pcan.2009.18",

language = "Ingl{\'e}s",

volume = "12",

pages = "296--300",

journal = "Prostate Cancer and Prostatic Diseases",

issn = "1365-7852",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - PTGS2-899G > C and prostate cancer risk

T2 - A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

AU - Murad, A.

AU - Lewis, S. J.

AU - Smith, G. Davey

AU - Collin, S. M.

AU - Chen, L.

AU - Hamdy, F. C.

AU - Neal, D. E.

AU - Donovan, J.

AU - Martin, R. M.

PY - 2009

Y1 - 2009

N2 - Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G > C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (ncases = 1608, ncontrols = 3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (ORCC & GC v GG = 1.05, 95% confidence interval (CI) = 0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled ORCC & GC v GG = 1.04, 95% CI = 0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.

AB - Prostaglandin endoperoxidase synthase 2 is a key regulator of inflammation and may play a role in prostate carcinogenesis. The polymorphism, -899G > C (rs20417), alters a transcription factor-binding site and is associated with a reduced risk of colorectal adenoma. We tested the hypothesis that rs20417 may influence prostate cancer risk, using a large case-control study (ncases = 1608, ncontrols = 3058). We found no evidence that rs20417 alters prostate cancer risk (odds ratio (ORCC & GC v GG = 1.05, 95% confidence interval (CI) = 0.91-1.20). A meta-analysis of three studies also found little evidence that rs20417 alters risk (pooled ORCC & GC v GG = 1.04, 95% CI = 0.93-1.17), making it unlikely that rs20417 contributes in any major way to prostate cancer aetiology.

UR - http://www.scopus.com/inward/record.url?scp=70249084836&partnerID=8YFLogxK

U2 - 10.1038/pcan.2009.18

DO - 10.1038/pcan.2009.18

M3 - Artículo de revisión

C2 - 19488068

AN - SCOPUS:70249084836

SN - 1365-7852

VL - 12

SP - 296

EP - 300

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

IS - 3

ER -

PTGS2-899G > C and prostate cancer risk: A population-based nested case-control study (ProtecT) and a systematic review with meta-analysis

Abstract

Access to Document

Other files and links

Fingerprint

Cite this